1Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention : the development of a clinical risk algorithm from the National Cardiovascular Data Registry[ J]. Circ Cardiovasc Interv, 2009, 2 ( 3 ) : 222-229. DOI : 10.1161/CIRCINTERVENTIONS. 108. 846741.
2Kinnaird T, Anderson R, Hill J, et al. Bleeding during percutaneous intervention: tailoring the approach to minimise risk [J]. Heart, 2009,95 ( 1 ) : 15-19. DOI: 10. 1136/hrt. 2007. 131284.
3Chhatriwalla AK, Amin AP, Kennedy KF, et al. Association between bleeding events and in-hospital mortality after pereutaneous coronary intervention[ J 1. JAMA, 2013, 309 (10) : 1022-1029. DOI : 10. 1001/jama. 2013.1556.
4Kwok CS, Khan MA, Rao SV, et al. Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis[ J ]. Circ Cardiovasc lnterv, 2015, 8 (4) : e001645. DOI: 10. 1161/CIRCINTERVENTIONS. 114. 001645.
5Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) [ J ]. Eur Heart J, 2003, 24 (20) :1815-1823.
6Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score [ J ]. Circulation, 2009, 119 ( 14 ): 1873-1882. DOI: 10. 1161/ CIRCULATIONAHA. 108. 828541.
7Ndrepepa G, Guerra E, Schulz S, et al. Correlates of poor outcome among patients with bleeding after coronary interventions [J]. Coron Artery Dis, 2014, 25(6) : 456-462. DOI:10, 1097/ MCA. 0000000000000126.
8Shivaraju A, Patel V, Fonarow GC, et al. Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database[J]. Am Heart J, 2011 , 162(6) : 1062- 1068. DOI:I0. 1016/j. ahj. 2011.09. 009.
9Dauerman HL, Rao SV, Resnie FS et al. Bleeding avoidance strategies. Consensus and controversy [ J]. J Am Coil Cardiol, 2011,58(1): 1-10. DOI:10.1016/j. jaec. 2011. 02. 039.
10Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials[ J]. BMJ,2015,350 : h1618.
5Lloyd-Jones D, Adams R J, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation,2010,121 : e46-e215.
6Touze E, Varenne O, Chatellier G, et al. Risk of myocardial infarction and vascular death after transient ischemic attack and ischemic stroke: a systematic review and meta-analysis. Stroke, 2005,36:2748-2755.
7Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA,1991,266:528-532.
8Cupples LA, Gagnon DR, Wong ND, et al. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham study. Am Heart J, 1993, 125 : 863-872.
9Ketley D, Woods KL. Selection factors for the use of thrombolytic treatment in acute myocardial infarction: a population based study of current practice in the United Kingdom. The European secondary prevention study group. Br Heart J,1995,74:224-228.
10Tanne D, Gottlieb S, Caspi A, et al. Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era: the Israeli thrombolytic national survey. Arch Intern Med, 1998,158: 601-606.
